


Author index of volume 63

- Abe, E., see Ikarashi, T. **63**, 11
- Agarwal, M.M., J. Punnose, G.S. Dhatt, Gestational diabetes: problems associated with the oral glucose tolerance test **63**, 73
- Ahn, J.D., see Park, K.-G. **63**, 135
- Aizawa, Y., see Ikarashi, T. **63**, 11
- Ajayi, A.A., G.O. Ogungbade, H.C. Hercule, A.O. Oyekan, L. Mutembei, Alteration in endothelin receptor sub-type responsiveness and in the endothelin-TXA₂ mimetic U46619 interaction, in type-2 hypertensive diabetic Zucker rats **63**, 155
- Aoki, I., see Tanaka, S.-i. **63**, 1
- Aragon, F.F., see Pimenta, W.P. **63**, 87
- Arroyo, P., see Sánchez-Corona, J. **63**, 47
- Aso, K., see Nakazaki, M. **63**, 171
- Atsumi, Y., see Suzuki, Y. **63**, 225
- Barrera, H., see Sánchez-Corona, J. **63**, 47
- Barrett, P.H.R., see Chan, D.C. **63**, 77
- Beaven, D.W., see Chen, F. **63**, 113
- Bugianesi, E., see Marchesini, G. **63**, 143
- Cappleman, J., see Shelmet, J. **63**, 27
- Casanueva, F., see Micic, D. **63**, 37
- Chan, D.C., G.F. Watts, A.V. Sussekov, P.H.R. Barrett, Z. Yang, J. Hua, S. Song, Adipose tissue compartments and insulin resistance in overweight-obese Caucasian men **63**, 77
- Chang, Y.-C., see Park, K.-G. **63**, 135
- Chen, F., C.M. Florkowski, M. Dever, D.W. Beaven, Death Certification and New Zealand Health Information Service (NZHIS) statistics for diabetes mellitus: an under-recognised health problem **63**, 113
- Chou, P., see Lin, T. **63**, 119
- Clifton, P.M., see Morris, A.M. **63**, 179
- Cvijovic, G., see Micic, D. **63**, 37
- Damm, P., see Stage, E. **63**, 67
- Dever, M., see Chen, F. **63**, 113
- Dhatt, G.S., see Agarwal, M.M. **63**, 73
- Dieguez, C., see Micic, D. **63**, 37
- Fernández, V., see Sánchez-Corona, J. **63**, 47
- Flores-Martínez, S.E., see Sánchez-Corona, J. **63**, 47
- Florkowski, C.M., see Chen, F. **63**, 113
- Forlani, G., see Marchesini, G. **63**, 143
- Fukudome, M., see Nakazaki, M. **63**, 171
- Fukui, M., Y. Kitagawa, N. Nakamura, M. Kadono, S.-i. Mogami, M. Ohnishi, C. Hirata, N. Ichio, K. Wada, C. Kishimoto, H. Okada, H. Miyata, T. Yoshikawa, Idiopathic sudden hearing loss in patients with type 2 diabetes **63**, 205
- Fukushige, E., see Nakazaki, M. **63**, 171
- Gåfvels, C., see Wändell, P.E. **63**, 195
- Galaviz-Hernández, C., see Sánchez-Corona, J. **63**, 47
- Gooch, B., see Jovanovic, L. **63**, 127
- Greco, S., see Jovanovic, L. **63**, 127
- Hale, P.M., see Jovanovic, L. **63**, 127
- Hanson, R.L., see Sánchez-Corona, J. **63**, 47
- Hanyu, O., see Ikarashi, T. **63**, 11
- Hashiguchi, H., see Nakazaki, M. **63**, 171
- Hassman, D.R., see Jovanovic, L. **63**, 127
- Hercule, H.C., see Ajayi, A.A. **63**, 155
- Hirata, C., see Fukui, M. **63**, 205
- Hori, M., see Katakami, N. **63**, 93
- Hua, J., see Chan, D.C. **63**, 77
- Ichio, N., see Fukui, M. **63**, 205
- Ikarashi, T., O. Hanyu, S. Maruyama, S. Souda, C. Kobayashi, E. Abe, J. Ukisu, K. Naganuma, A. Suzuki, M. Toya, S. Kaneko, K. Suzuki, O. Nakagawa, Y. Aizawa, Genotype Gly/Gly of the Arg16Gly polymorphism of the β_2 -adrenergic receptor is associated with elevated fasting serum insulin concentrations, but not with acute insulin response to glucose, in type 2 diabetic patients, **63**, 11
- Ikeda, Y., see Nakazaki, M. **63**, 171
- Ishibashi, S., see Yatagai, T. **63**, 19
- Ishikawa, S.-e., see Yatagai, T. **63**, 19
- Jain, R., see Jovanovic, L. **63**, 127
- James, R., see Kerenyi, Z. **63**, 213
- Jovanovic, L., D.R. Hassman, B. Gooch, R. Jain, S. Greco, N. Khutoryansky, P.M. Hale, Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone **63**, 127
- Kadono, M., see Fukui, M. **63**, 205
- Kajimoto, Y., see Katakami, N. **63**, 93
- Kamei, J., see Tanaka, S.-i. **63**, 1
- Kaneko, S., see Ikarashi, T. **63**, 11

- Katakami, N., Y. Yamasaki, K. Kosugi, H. Waki, M. Matsuhisa, Y. Kajimoto, T. Masuyama, M. Hori, Tissue characterization identifies subjects with high risk of cardiovascular diseases **63**, 93
- Kato, K., see Nakazaki, M. **63**, 171
- Kemp, J., see van de Laar, F.A. **63**, 57
- Kendereski, A., see Micic, D. **63**, 37
- Kerenyi, Z., H. Samer, R. James, Y. Yan, M. Stewart, Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus **63**, 213
- Khutoryansky, N., see Jovanovic, L. **63**, 127
- Kim, H.-S., see Park, K.-G. **63**, 135
- Kim, M.-J., see Park, K.-G. **63**, 135
- Kimura, M., see Tanaka, S.-i. **63**, 1
- Kishimoto, C., see Fukui, M. **63**, 205
- Kitagawa, Y., see Fukui, M. **63**, 205
- Kobayashi, C., see Ikarashi, T. **63**, 11
- Koriyama, N., see Nakazaki, M. **63**, 171
- Kosugi, K., see Katakami, N. **63**, 93
- Kusaka, I., see Yatagai, T. **63**, 19
- Laviada-Molina, H.A., see Sánchez-Corona, J. **63**, 47
- Lee, I.-K., see Park, K.-G. **63**, 135
- Lee, Y.-C., see Lin, T. **63**, 119
- Ley, S.J., P.A. Metcalf, R.K.R. Scragg, B.A. Swinburn, Long-term effects of a reduced fat diet intervention on cardiovascular disease risk factors in individuals with glucose intolerance **63**, 103
- Liang, J., see Shelmet, J. **63**, 27
- Lin, T., P. Chou, S.-T. Tsai, Y.-C. Lee, T.-Y. Tai, Predicting factors associated with costs of diabetic patients in Taiwan **63**, 119
- Lucassen, P.L.B.J., see van de Laar, F.A. **63**, 57
- Lyness, W., see Shelmet, J. **63**, 27
- Lytzen, L., see Shelmet, J. **63**, 27
- Machorro-Lazo, M.V., see Sánchez-Corona, J. **63**, 47
- Manini, R., see Marchesini, G. **63**, 143
- Marchesini, G., E. Bugianesi, G. Forlani, R. Marzocchi, C. Zannoni, E. Vanni, R. Manini, M. Rizzetto, N. Melchionda, Non-alcoholic steatohepatitis in patients cared in metabolic units **63**, 143
- Maruyama, S., see Ikarashi, T. **63**, 11
- Marzocchi, R., see Marchesini, G. **63**, 143
- Masuyama, T., see Katakami, N. **63**, 93
- Matsuhisa, M., see Katakami, N. **63**, 93
- Matsuo, Y., see Nakanishi, N. **63**, 185
- Matsuoka, K., see Suzuki, Y. **63**, 225
- Melchionda, N., see Marchesini, G. **63**, 143
- Metcalf, P.A., see Ley, S.J. **63**, 103
- Micic, D., A. Kendereski, M. Sumarac-Dumanovic, G. Cvijovic, V. Popovic, C. Dieguez, F. Casanueva, Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp **63**, 37
- Miyata, H., see Fukui, M. **63**, 205
- Mobbs, C., see Tanaka, S.-i. **63**, 1
- Mogami, S.-i., see Fukui, M. **63**, 205
- Morán-Moguel, M.C., see Sánchez-Corona, J. **63**, 47
- Morris, A.M., M. Noakes, P.M. Clifton, In vitro mononuclear cell production of tumour necrosis factor- α and weight loss **63**, 179
- Mújica-López, K.I., see Sánchez-Corona, J. **63**, 47
- Muramatsu, T., see Suzuki, Y. **63**, 225
- Mutembei, L., see Ajayi, A.A. **63**, 155
- Naganuma, K., see Ikarashi, T. **63**, 11
- Nagasaka, S., see Yatagai, T. **63**, 19
- Nakagawa, O., see Ikarashi, T. **63**, 11
- Nakamura, N., see Fukui, M. **63**, 205
- Nakamura, T., see Yatagai, T. **63**, 19
- Nakanishi, N., K. Nishina, M. Okamoto, H. Yoshida, Y. Matsuo, K. Suzuki, K. Tatara, Clustering of components of the metabolic syndrome and risk for development of type 2 diabetes in Japanese male office workers **63**, 185
- Nakazaki, M., E. Fukushige, N. Koriyama, M. Fukudome, H. Hashiguchi, K. Aso, J. Yano, Y. Ikeda, K. Kato, C. Tei, Strongest correlation of HbA_{1c} with 1-month-earlier glucose levels in type 2 diabetes **63**, 171
- Nicklasson, L., see Shelmet, J. **63**, 27
- Nishimaki, K., see Suzuki, Y. **63**, 225
- Nishina, K., see Nakanishi, N. **63**, 185
- Noakes, M., see Morris, A.M. **63**, 179
- Ogunbade, G.O., see Ajayi, A.A. **63**, 155
- Ohnishi, M., see Fukui, M. **63**, 205
- Ohta, S., see Suzuki, Y. **63**, 225
- Okada, H., see Fukui, M. **63**, 205
- Okamoto, M., see Nakanishi, N. **63**, 185
- Okuda, K., see Tanaka, S.-i. **63**, 1
- Oyekan, A.O., see Ajayi, A.A. **63**, 155
- Padovani, C.R., see Pimenta, W.P. **63**, 87
- Pardío, J., see Sánchez-Corona, J. **63**, 47
- Park, K.-G., K.S. Park, M.-J. Kim, H.-S. Kim, Y.-S. Suh, J.D. Ahn, K.-K. Park, Y.-C. Chang, I.-K. Lee, Relationship between serum adiponectin and leptin concentrations and body fat distribution **63**, 135
- Park, K.-K., see Park, K.-G. **63**, 135
- Park, K.S., see Park, K.-G. **63**, 135
- Perea, F.J., see Sánchez-Corona, J. **63**, 47
- Peterson, G., see Shelmet, J. **63**, 27
- Pimenta, W.P., M.V.C. Rudge, F.F. Aragon, C.R. Padovani, Pancreatic β -cell defects in women at risk of type 2 diabetes **63**, 87
- Popovic, V., see Micic, D. **63**, 37
- Punnose, J., see Agarwal, M.M. **63**, 73
- Rizzetto, M., see Marchesini, G. **63**, 143
- Ronneby, H., see Stage, E. **63**, 67
- Rudge, M.V.C., see Pimenta, W.P. **63**, 87
- Rutten, G.E.H.M., see van de Laar, F.A. **63**, 57
- Samer, H., see Kerenyi, Z. **63**, 213
- Sánchez-Corona, J., S.E. Flores-Martínez, M.V. Machorro-Lazo, C. Galaviz-Hernández, M.C. Morán-Moguel, F.J. Perea, K.I. Mújica-López, L. Vargas-Ancona, H.A. Laviada-Molina, V. Fernández, J. Pardío, P. Arroya, H. Barrera, R.L. Hanson, Polymorphisms in candidate genes for type 2 diabetes mellitus in a Mexican population with metabolic syndrome findings **63**, 47

- Schwartz, S., see Shelmet, J. 63, 27
- Scragg, R.K.R., see Ley, S.J. 63, 103
- Shelmet, J., S. Schwartz, J. Cappleman, G. Peterson, S. Skovlund, L. Lytzen, L. Nicklasson, J. Liang, W. Lyness, Preference and resource utilization in elderly patients: InnoLet[®] versus vial/syringe 63, 27
- Skovlund, S., see Shelmet, J. 63, 27
- Song, S., see Chan, D.C. 63, 77
- Souda, S., see Ikarashi, T. 63, 11
- Stage, E., H. Ronneby, P. Damm, Lifestyle change after gestational diabetes 63, 67
- Stewart, M., see Kerenyi, Z. 63, 213
- Suh, Y.-S., see Park, K.-G. 63, 135
- Sumarac-Dumanovic, M., see Micic, D. 63, 37
- Sussekov, A.V., see Chan, D.C. 63, 77
- Suzuki, A., see Ikarashi, T. 63, 11
- Suzuki, K., see Ikarashi, T. 63, 11
- Suzuki, K., see Nakanishi, N. 63, 185
- Suzuki, Y., K. Nishimaki, M. Taniyama, T. Muramatsu, Y. Atsumi, K. Matsuoka, S. Ohta, Lipoma and ophthalmoplegia in mitochondrial diabetes associated with small heteroplasmy level of 3243 tRNA^{Leu(UUR)} mutation 63, 225
- Swinburn, B.A., see Ley, S.J. 63, 103
- Tai, T.-Y., see Lin, T. 63, 119
- Tanaka, S.-i., T. Yamakawa, M. Kimura, I. Aoki, J. Kamei, K. Okuda, C. Mobbs, Daily nasal inoculation with the insulin gene ameliorates diabetes in mice 63, 1
- Taniyama, M., see Suzuki, Y. 63, 225
- Tatara, K., see Nakanishi, N. 63, 185
- Tei, C., see Nakazaki, M. 63, 171
- Toya, M., see Ikarashi, T. 63, 11
- Tsai, S.-T., see Lin, T. 63, 119
- Ukisu, J., see Ikarashi, T. 63, 11
- van de Laar, F.A., P.L.B.J. Lucassen, J. Kemp, E.H. van de Lisdonk, C. van Weel, G.E.H.M. Rutten, Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial 63, 57
- van de Lisdonk, E.H., see van de Laar, F.A. 63, 57
- van Weel, C., see van de Laar, F.A. 63, 57
- Vanni, E., see Marchesini, G. 63, 143
- Vargas-Ancona, L., see Sánchez-Corona, J. 63, 47
- Wada, K., see Fukui, M. 63, 205
- Waki, H., see Katakami, N. 63, 93
- Wändell, P.E., C. Gåfvels, Patients with type 2 diabetes aged 35–64 years at four primary health care centres in Stockholm County, Sweden. Prevalence and complications in relation to gender and socio-economic status 63, 195
- Watts, G.F., see Chan, D.C. 63, 77
- Yamakawa, T., see Tanaka, S.-i. 63, 1
- Yamasaki, Y., see Katakami, N. 63, 93
- Yan, Y., see Kerenyi, Z. 63, 213
- Yang, Z., see Chan, D.C. 63, 77
- Yano, J., see Nakazaki, M. 63, 171
- Yatagai, T., T. Nakamura, S. Nagasaka, I. Kusaka, S.-e. Ishikawa, A. Yoshitaka, S. Ishibashi, Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects 63, 19
- Yoshida, H., see Nakanishi, N. 63, 185
- Yoshikawa, T., see Fukui, M. 63, 205
- Yoshitaka, A., see Yatagai, T. 63, 19
- Zannoni, C., see Marchesini, G. 63, 143



Subject index of volume 63

β_2 -Adrenergic receptor; Genetic polymorphism; Type 2 diabetes mellitus; Insulin secretion **63**, 11

Adiponectin; Leptin; Visceral adipose tissue; Subcutaneous adipose tissue; Obesity **63**, 135

Atherosclerosis; Cardiovascular diseases; Carotid artery; Tissue characterization; Integrated backscatter **63**, 93

Blood pressure; Glucose intolerance; Reduced fat diet; Cardiovascular disease risk factors; Cholesterol **63**, 103

C-reactive protein; Troglitazone; Metformin; Insulin resistance **63**, 19

Candidate genes; Metabolic syndrome; Genetics; Type 2 diabetes mellitus; Insulin **63**, 47

Cardiovascular disease risk factors; Glucose intolerance; Reduced fat diet; Cholesterol; Blood pressure **63**, 103

Cardiovascular disease; Visceral obesity; Humans; Metabolic syndrome; Insulin resistance **63**, 77

Cardiovascular diseases; Atherosclerosis; Carotid artery; Tissue characterization; Integrated backscatter **63**, 93

Carotid artery; Cardiovascular diseases; Atherosclerosis; Tissue characterization; Integrated backscatter **63**, 93

Cholesterol; Glucose intolerance; Reduced fat diet; Cardiovascular disease risk factors; Blood pressure **63**, 103

Clinical coding; Mortality; Death certificates; Diabetes mellitus **63**, 113

Cluster; Type 2 diabetes; Metabolic syndrome; Longitudinal study; Japanese men **63**, 185

Combination therapy; Insulin secretagogues; Thiazolidinedione; OAD monotherapy failure **63**, 127

Combination therapy; Rosiglitazone; Glibenclamide; Thiazolidinediones; Sulphonylureas **63**, 213

Costs; Diabetes; Predicting factors **63**, 119

Death certificates; Mortality; Clinical coding; Diabetes mellitus **63**, 113

Diabetes mellitus; Gene transfer; Nasal administration; Liposome **63**, 1

Diabetes mellitus; Mortality; Death certificates; Clinical coding **63**, 113

Diabetes mellitus; Primary health care; Gender; Socio-economic status; Sweden **63**, 195

Diabetes, non-insulin dependent; Obesity; Hyperlipidemia; Fatty liver; Metabolic syndrome X **63**, 143

Diabetes; Costs; Predicting factors **63**, 119

Endothelin receptors; Type-2 diabetes; Zucker rats; Thromboxanes; Endotheliopathy; Endothelin-B receptor antagonists **63**, 155

Endothelin-B receptor antagonists; Type-2 diabetes; Zucker rats; Endothelin receptors; Thromboxanes; Endotheliopathy **63**, 155

Endotheliopathy; Type-2 diabetes; Zucker rats; Endothelin receptors; Thromboxanes; Endothelin-B receptor antagonists **63**, 155

Euglycemic clamp; Growth hormone; GHRH + GHRP-6; Hyperglycemic clamp; Type 2 diabetes **63**, 37

Fatty liver; Diabetes, non-insulin dependent; Obesity; Hyperlipidemia; Metabolic syndrome X **63**, 143

- Gender**; Diabetes mellitus; Primary health care; Socio-economic status; Sweden **63**, 195
- Gene transfer**; Diabetes mellitus; Nasal administration; Liposome **63**, 1
- General practice**; Sulphonylurea; α -Glucosidase inhibitor; The Netherlands **63**, 57
- Genetic polymorphism**; β_2 -Adrenergic receptor; Type 2 diabetes mellitus; Insulin secretion **63**, 11
- Genetics**; Metabolic syndrome; Type 2 diabetes mellitus; Candidate genes; Insulin **63**, 47
- Gestational diabetes**; Oral glucose tolerance test; Limitations **63**, 73
- Gestational hyperglycemia**; Insulin release; Insulin sensitivity; Type 2 diabetes **63**, 87
- GHRH + GHRP-6**; Growth hormone; Euglycemic clamp; Hyperglycemic clamp; Type 2 diabetes **63**, 37
- Glibenclamide**; Rosiglitazone; Thiazolidinediones; Combination therapy; Sulphonylureas **63**, 213
- α -Glucosidase inhibitor**; General practice; Sulphonylurea; The Netherlands **63**, 57
- Glucose intolerance**; Reduced fat diet; Cardiovascular disease risk factors; Cholesterol; Blood pressure **63**, 103
- Growth hormone**; GHRH + GHRP-6; Euglycemic clamp; Hyperglycemic clamp; Type 2 diabetes **63**, 37
- HbA_{1c} and plasma glucose**; Type 2 diabetes mellitus; Outpatient **63**, 171
- Healthcare costs**; Insulin delivery systems; Quality of life; Patient independence; Patient acceptance **63**, 27
- Humans**; Visceral obesity; Metabolic syndrome; Insulin resistance; Cardiovascular disease **63**, 77
- Hyperglycemic clamp**; Growth hormone; GHRH + GHRP-6; Euglycemic clamp; Type 2 diabetes **63**, 37
- Hyperlipidemia**; Diabetes, non-insulin dependent; Obesity; Fatty liver; Metabolic syndrome X **63**, 143
- Idiopathic sudden hearing loss**; Type 2 diabetes; Severity of hearing loss **63**, 205
- Insulin delivery systems**; Healthcare costs; Quality of life; Patient independence; Patient acceptance **63**, 27
- Insulin release**; Gestational hyperglycemia; Insulin sensitivity; Type 2 diabetes **63**, 87
- Insulin resistance**; Troglitazone; Metformin; C-reactive protein **63**, 19
- Insulin resistance**; Visceral obesity; Humans; Metabolic syndrome; Cardiovascular disease **63**, 77
- Insulin secretagogues**; Thiazolidinedione; Combination therapy; OAD monotherapy failure **63**, 127
- Insulin secretion**; β_2 -Adrenergic receptor; Genetic polymorphism; Type 2 diabetes mellitus **63**, 11
- Insulin sensitivity**; Gestational hyperglycemia; Insulin release; Type 2 diabetes **63**, 87
- Insulin**; Metabolic syndrome; Genetics; Type 2 diabetes mellitus; Candidate genes **63**, 47
- Integrated backscatter**; Cardiovascular diseases; Atherosclerosis; Carotid artery; Tissue characterization **63**, 93
- Japanese men**; Type 2 diabetes; Metabolic syndrome; Cluster; Longitudinal study **63**, 185
- Leptin**; Adiponectin; Visceral adipose tissue; Subcutaneous adipose tissue; Obesity **63**, 135
- Lifestyle**; Previous gestational diabetes **63**, 67
- Limitations**; Gestational diabetes; Oral glucose tolerance test **63**, 73
- Lipoma**; Oculomotor palsy; 3243 mitochondrial DNA mutation; Mitochondrial diabetes **63**, 225
- Liposome**; Diabetes mellitus; Gene transfer; Nasal administration **63**, 1
- Longitudinal study**; Type 2 diabetes; Metabolic syndrome; Cluster; Japanese men **63**, 185
- Metabolic syndrome X**; Diabetes, non-insulin dependent; Obesity; Hyperlipidemia; Fatty liver **63**, 143

- Metabolic syndrome;** Genetics; Type 2 diabetes mellitus; Candidate genes; Insulin **63**, 47
- Metabolic syndrome;** Type 2 diabetes; Cluster; Longitudinal study; Japanese men **63**, 185
- Metabolic syndrome;** Visceral obesity; Humans; Insulin resistance; Cardiovascular disease **63**, 77
- Metformin;** Troglitazone; C-reactive protein; Insulin resistance **63**, 19
- Mitochondrial diabetes;** Lipoma; Oculomotor palsy; 3243 mitochondrial DNA mutation **63**, 225
- 3243 mitochondrial DNA mutation;** Lipoma; Oculomotor palsy; Mitochondrial diabetes **63**, 225
- Mononuclear cell;** Obesity; TNF- α ; Weight loss; Type 2 diabetes **63**, 179
- Mortality;** Death certificates; Clinical coding; Diabetes mellitus **63**, 113
- Nasal administration;** Diabetes mellitus; Gene transfer; Liposome **63**, 1
- OAD monotherapy failure;** Insulin secretagogues; Thiazolidinedione; Combination therapy **63**, 127
- Obesity;** Adiponectin; Leptin; Visceral adipose tissue; Subcutaneous adipose tissue **63**, 135
- Obesity;** Diabetes, non-insulin dependent; Hyperlipidemia; Fatty liver; Metabolic syndrome X **63**, 143
- Obesity;** TNF- α ; Weight loss; Type 2 diabetes; Mononuclear cell **63**, 179
- Oculomotor palsy;** Lipoma; 3243 mitochondrial DNA mutation; Mitochondrial diabetes **63**, 225
- Oral glucose tolerance test;** Gestational diabetes; Limitations **63**, 73
- Outpatient;** Type 2 diabetes mellitus; HbA_{1c} and plasma glucose **63**, 171
- Patient acceptance;** Insulin delivery systems; Healthcare costs; Quality of life; Patient independence **63**, 27
- Patient independence;** Insulin delivery systems; Healthcare costs; Quality of life; Patient acceptance **63**, 27
- Predicting factors;** Diabetes; Costs **63**, 119
- Previous gestational diabetes;** Lifestyle **63**, 67
- Primary health care;** Diabetes mellitus; Gender; Socio-economic status; Sweden **63**, 195
- Quality of life;** Insulin delivery systems; Healthcare costs; Patient independence; Patient acceptance **63**, 27
- Reduced fat diet;** Glucose intolerance; Cardiovascular disease risk factors; Cholesterol; Blood pressure **63**, 103
- Rosiglitazone;** Glibenclamide; Thiazolidinediones; Combination therapy; Sulphonylureas **63**, 213
- Severity of hearing loss;** Type 2 diabetes; Idiopathic sudden hearing loss **63**, 205
- Socio-economic status;** Diabetes mellitus; Primary health care; Gender; Sweden **63**, 195
- Subcutaneous adipose tissue;** Adiponectin; Leptin; Visceral adipose tissue; Obesity **63**, 135
- Sulphonylurea;** General practice; α -Glucosidase inhibitor; The Netherlands **63**, 57
- Sulphonylureas;** Rosiglitazone; Glibenclamide; Thiazolidinediones; Combination therapy **63**, 213
- Sweden;** Diabetes mellitus; Primary health care; Gender; Socio-economic status **63**, 195
- The Netherlands;** General practice; Sulphonylurea; α -Glucosidase inhibitor **63**, 57
- Thiazolidinedione;** Insulin secretagogues; Combination therapy; OAD monotherapy failure **63**, 127
- Thiazolidinediones;** Rosiglitazone; Glibenclamide; Combination therapy; Sulphonylureas **63**, 213
- Thromboxanes;** Type-2 diabetes; Zucker rats; Endothelin receptors; Endotheliopathy; Endothelin-B receptor antagonists **63**, 155
- Tissue characterization;** Cardiovascular diseases; Atherosclerosis; Carotid artery; Integrated backscatter **63**, 93

TNF- α ; Obesity; Weight loss; Type 2 diabetes; Mononuclear cell **63**, 179

Troglitazone; Metformin; C-reactive protein; Insulin resistance **63**, 19

Type 2 diabetes mellitus; β_2 -Adrenergic receptor; Genetic polymorphism; Insulin secretion **63**, 11

Type 2 diabetes mellitus; Metabolic syndrome; Genetics; Candidate genes; Insulin **63**, 47

Type 2 diabetes mellitus; Outpatient; HbA_{1c} and plasma glucose **63**, 171

Type 2 diabetes; Gestational hyperglycemia; Insulin release; Insulin sensitivity **63**, 87

Type 2 diabetes; Growth hormone; GHRH + GHRP-6; Euglycemic clamp; Hyperglycemic clamp **63**, 37

Type 2 diabetes; Idiopathic sudden hearing loss; Severity of hearing loss **63**, 205

Type 2 diabetes; Metabolic syndrome; Cluster; Longitudinal study; Japanese men **63**, 185

Type 2 diabetes; Obesity; TNF- α ; Weight loss; Mononuclear cell **63**, 179

Type-2 diabetes; Zucker rats; Endothelin receptors; Thromboxanes; Endotheliopathy; Endothelin-B receptor antagonists **63**, 155

Visceral adipose tissue; Adiponectin; Leptin; Subcutaneous adipose tissue; Obesity **63**, 135

Visceral obesity; Humans; Metabolic syndrome; Insulin resistance; Cardiovascular disease **63**, 77

Weight loss; Obesity; TNF- α ; Type 2 diabetes; Mononuclear cell **63**, 179

Zucker rats; Type-2 diabetes; Endothelin receptors; Thromboxanes; Endotheliopathy; Endothelin-B receptor antagonists **63**, 155